My site

− Approval based on AETHERA Phase 3 data demonstrating 75 percent improvement in progression-free survival (PFS) for patients treated with ADCETRIS as consolidation therapy immediately following autologous stem cell transplant (ASCT) −

CAMBRIDGE, Mass. & OSAKA, Japan - Friday, July 8th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) has extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT). The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on May 26, 2016.

“Relapse is a devastating event for patients with Hodgkin lymphoma and their families. Not only is the emotional impact significant, b ... Read more »

LAUSANNE, Switzerland - Saturday, July 9th 2016 [ME NewsWire]

(BUSINESS WIRE)-- Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today comments on the decision of an ICSID tribunal in the arbitration between PMI and Uruguay regarding two regulations that Uruguay implemented in 2009. PMI brought the case under Uruguay’s 1988 investment protection treaty with Switzerland, which provides a neutral forum for dispute resolution.

Marc Firestone, Philip Morris International Senior Vice President and General Counsel, said:

“For the last seven years, we have already been complying with the regulations at issue in the case, so today’s outcome doesn’t change the status quo. We’ve never questioned Uruguay’s authority to protect public health, and this case wasn’t about broad issues of tobacco policy. The arbitration concerned an important, but unusual, set of facts that called for clarification under international ... Read more »